You are here:
Imbruvica
Imbruvica in combination with R-CHOP or R-DHAP for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are eligible for autologous stem cell transplantation (ASCT).
No estimate possible yet
1,338,064.00
Clinical trials
Ibrutinib
Hematology
Indication extension
Aggressive non-Hodgkin’s lymphoma
Janssen
Tyrosine kinase inhibitor
Oral
Tablet
Intermural (MSZ)
Proteïnekinaseremmer. Remt irreversibel Bruton’s tyrosinekinase.
Centralised (EMA)
Normal trajectory
No
July 2024
January 2025
Yes
inductie met R-CHOP/R-DHAP gevolgd door ASCT
1 times a day
560 mg
16
Market share is generally not included unless otherwise stated.
NKR; Fabrikant; Budget impact analyse van ibrutinib (Imbruvica) bij de behandeling van chronische lymfatische leukemie (patiënten zonder 17p of TP53 mutaties)
De incidentie van MCL in Nederland was in 2015, 187 patiënten waarvan 130 patiënten ouder zijn dan 65 jaar. Ongeveer 12% van de patiënten hiervan komt in aanmerking voor deze behandeling. Het geschatte aantal patiënten komt daarmee op 12% x 130 = 16 patiënten per jaar.
83,629.00
G-standaard; fabrikant
Lijstprijs (€57,28/tablet 140mg) x maximaal gebruik per jaar (4 tabletten/dag x 365 dagen) = €83.629.
This amount gives an indication of the total cost. It is the result of the average expected patient volume times the average cost per patient. both per year.
There is currently nothing known about off label use.
There is currently no futher information available.
Understanding of expected market entry of innovative medicines